ATE366812T1 - Neue methode zur erkennung eines stoffes, der die interaktion zwischen einem tnf-liganden und seinem rezeptor auf b-zellen moduliert - Google Patents

Neue methode zur erkennung eines stoffes, der die interaktion zwischen einem tnf-liganden und seinem rezeptor auf b-zellen moduliert

Info

Publication number
ATE366812T1
ATE366812T1 AT99950598T AT99950598T ATE366812T1 AT E366812 T1 ATE366812 T1 AT E366812T1 AT 99950598 T AT99950598 T AT 99950598T AT 99950598 T AT99950598 T AT 99950598T AT E366812 T1 ATE366812 T1 AT E366812T1
Authority
AT
Austria
Prior art keywords
modulates
receptor
interaction
substance
cells
Prior art date
Application number
AT99950598T
Other languages
English (en)
Inventor
Stuart Neville Farrow
Allard Kaptein
Jeremy David Alisdair Kitson
Alison Janet Winder
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10845021&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366812(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE366812T1 publication Critical patent/ATE366812T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT99950598T 1998-12-23 1999-10-05 Neue methode zur erkennung eines stoffes, der die interaktion zwischen einem tnf-liganden und seinem rezeptor auf b-zellen moduliert ATE366812T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828628.9A GB9828628D0 (en) 1998-12-23 1998-12-23 Novel ligand

Publications (1)

Publication Number Publication Date
ATE366812T1 true ATE366812T1 (de) 2007-08-15

Family

ID=10845021

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99950598T ATE366812T1 (de) 1998-12-23 1999-10-05 Neue methode zur erkennung eines stoffes, der die interaktion zwischen einem tnf-liganden und seinem rezeptor auf b-zellen moduliert

Country Status (8)

Country Link
US (4) US7399593B1 (de)
EP (2) EP1847608B1 (de)
AT (1) ATE366812T1 (de)
AU (1) AU6332399A (de)
DE (1) DE69936538T2 (de)
ES (2) ES2289825T3 (de)
GB (1) GB9828628D0 (de)
WO (1) WO2000039295A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
DK1146892T3 (da) 1999-01-25 2003-11-24 Apoxis Sa BAFF, inhibitorer deraf og deres anvendelse i modulationen af B-celle responset
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
IL148089A0 (en) 1999-08-17 2002-09-12 Biogen Inc Baff receptor (bcma), an immunorgulatory agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2001288301A1 (en) * 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
NZ543174A (en) 2003-03-28 2008-09-26 Biogen Idec Inc Truncated BAFF receptors
AU2004315198A1 (en) 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of BCMA and uses thereof
EP2332563A3 (de) 2004-10-13 2013-03-13 The Washington University Verwendung von BAFF zur Behandlung von Sepsis
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EA016083B1 (ru) 2005-08-09 2012-02-28 Займоджинетикс, Инк. СПОСОБ ЛЕЧЕНИЯ НЕХОДЖКИНСКОЙ ЛИМФОМЫ С ПОМОЩЬЮ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
NZ568204A (en) * 2005-10-13 2012-01-12 Human Genome Sciences Inc Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
WO2010093993A2 (en) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
ATE302272T1 (de) * 1996-10-25 2005-09-15 Human Genome Sciences Inc Neutrokin alpha
US6689579B1 (en) * 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
AU743490B2 (en) * 1997-06-06 2002-01-24 Regeneron Pharmaceuticals, Inc. NTN-2 member of TNF ligand family
AU7608898A (en) 1997-06-06 1998-12-21 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
EA200000311A1 (ru) 1997-09-12 2000-10-30 Апотек Р Энд Д Са Новый белок иммунной системы - кау
US6157933A (en) 1997-11-26 2000-12-05 International Business Machines Corporation Method and apparatus for loading multiple animated images on a web-page with limited network throughput
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
DK1146892T3 (da) 1999-01-25 2003-11-24 Apoxis Sa BAFF, inhibitorer deraf og deres anvendelse i modulationen af B-celle responset
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
IL148089A0 (en) 1999-08-17 2002-09-12 Biogen Inc Baff receptor (bcma), an immunorgulatory agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci

Also Published As

Publication number Publication date
EP1141283A1 (de) 2001-10-10
DE69936538D1 (de) 2007-08-23
ES2621858T3 (es) 2017-07-05
ES2289825T3 (es) 2008-02-01
EP1141283B1 (de) 2007-07-11
AU6332399A (en) 2000-07-31
US7399593B1 (en) 2008-07-15
US20140056900A1 (en) 2014-02-27
US8216576B2 (en) 2012-07-10
DE69936538T2 (de) 2008-03-13
US20150197565A1 (en) 2015-07-16
EP1847608A1 (de) 2007-10-24
US20090098129A1 (en) 2009-04-16
EP1847608B1 (de) 2017-01-25
GB9828628D0 (en) 1999-02-17
US8784814B2 (en) 2014-07-22
WO2000039295A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
ATE366812T1 (de) Neue methode zur erkennung eines stoffes, der die interaktion zwischen einem tnf-liganden und seinem rezeptor auf b-zellen moduliert
IL124728A0 (en) Diagnosis and treatment of aur-1 and/or aur-2 related disorders
ATE364696T1 (de) Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
NZ527053A (en) Modified amyloid precursor protein polynucleotides and polypeptides
ATE449850T1 (de) Mutanten von flt3-l und ihre verwendungen
BR9912545A (pt) ácidos nucleicos codificando um receptorcopulado a proteìna g envolvido em transduçãosensorial
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
DE3765138D1 (de) Mehrschichtiges element zur quantitativen analyse von immunoreagenzien.
EP0299741A3 (de) Verfahren und Vorrichtung zur Sequenzierung von Proteinen oder Peptiden
DE69432449D1 (de) Verfahren zur Herstellung von hydrophoben Polypeptiden, Proteinen und Peptiden
ATE152481T1 (de) Neue polypeptide, dna-sequenzen, die deren expression erlauben, verfahren zur vorbereitung und verwendung
AP9901607A0 (en) Method and apparatus for continuous flow isoelectric focusing for
DE3650676D1 (de) Verfahren und mittel zur sortierung und bestimmung biologischer informationen
EP1609864A3 (de) Verwendung von dem neuronalen Apoptosehemstoff Protein (NAIP)
DE69328060D1 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
DE69704269D1 (de) Dendritische, lysinhaltige Polypeptide zur gezielten Arzneimittelabreichung
ATE301712T1 (de) Z2-19a, ein menschliches homolog von dem protein 2-19
DE69635739D1 (de) Verwendung eines sec-abhängigen sekretionssystems zur sekretion von proteinen, welche gewöhnlich durch ein sec-unabhängiges sekretionssystem sekretiert werden
DK1342729T3 (da) Antistoffer og antisense-molekyler for G-koblet receptor der udviser selektiv affinitet for ATP
GB9701045D0 (en) Diagnosis of neuro-degenerative disorders
DE69327167D1 (de) Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung
EP0840115A3 (de) DNA-Basen Sequenzer
DE69000909D1 (de) Transportables brueckenteil zur ueberwindung von graeben.
ITRM950434A0 (it) Polipeptide per la riparazione di informazione genetica, sequenza nucleotidica che codifica per esso e procedimento per la sua preparazione.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties